Pharmafile Logo

Smarter science, sharper strategy: Expert insights from ASCO® 2026

September 22, 2026 | ASCO, Congress, Pharma, healthcare, oncology 

As the oncology landscape continues to evolve, life sciences organizations face a growing challenge: how do you communicate increasingly complex science in a way that creates meaningful engagement?

- PMLiVE

The pace of innovation in oncology is accelerating, bringing more data, more complex science, and more information for HCPs to navigate.

Our latest oncology congress eBook explores what this means for life sciences organizations and how congress experiences can help turn scientific innovation into understanding.

Discover insights on:

  • Making meaningful connections in an age of accelerated innovation

  • Creating more effective congress experiences

  • The future of congress engagement for life sciences companies

  • Emerging trends shaping oncology commercialization

  • Why a connected approach is key to congress success

Explore the insights

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Blending qual and quant – the benefits of a hybrid approach

My colleague Chris Gaj and I recently conducted a video dialogue on the topic of hybrid qual/quant methods in which we discussed why clients often want to blend the two, and the…

Multi-level Segmentation Solution

Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different…

Global health care specialists from coast to coast

Published in Quirk’s Faces of Marketing Research August 2017

Demand assessment research video

Head of Business Analytics Tom Nolte and Associate Director Will Tolley discuss demand assessment research – the various techniques and when in a product’s stage of development a demand assessment…

Men vs Women in emerging markets

Our latest interactive infographic compares male vs female health characteristics in the BRIC emerging marketS

South Korea: The next global player?

In this paper, we will explore some of the key trends and outlooks for South Korea in more detail, including what lies behind its presence at the extremes of two…

20 questions: Round 4

As it’s our 20th year anniversary, we invited our employees to play our version of 20 questions – this month “What’s been the funniest thing to happen to you whilst you’ve…

Will gene therapies finally be commercially viable to pharma?

Our latest Free Thinking white paper explores the science behind the idea of gene therapy and takes a look at some of the core challenges medical researchers have faced when…

Wargaming in HCV

The challenge:Our client had a product ready for launch in the HCV landscape. A number of new competitor products were expected to alter the market dynamics. Given the stage of…

Living with Lupus: Breaking the Silence

Published in eyeforpharma July 2017 by Mariel Metcalfe